(SRPT) Sarepta Therapeutics - Ratings and Ratios
Gene Therapy, Antisense, Duchenne, Exon Skipping
SRPT EPS (Earnings per Share)
SRPT Revenue
Description: SRPT Sarepta Therapeutics
Sarepta Therapeutics Inc (NASDAQ:SRPT) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock is classified under the GICS Sub Industry of Biotechnology, indicating its primary focus on developing treatments for rare diseases.
To evaluate SRPTs financial health, we can examine key performance indicators (KPIs) such as revenue growth, net income, and operating expenses. The companys income tax expense is a relevant metric, as it can impact net income and cash flows. A thorough analysis of SRPTs tax strategy and its impact on profitability is essential.
SRPTs market capitalization is approximately $1.68 billion, suggesting a moderate level of market presence. The forward price-to-earnings (P/E) ratio is around 9.84, indicating that investors expect the company to generate earnings in the future. However, the current P/E ratio is not available, likely due to the companys current net loss. The return on equity (RoE) is -20.00%, highlighting the companys current unprofitability.
Key economic drivers for SRPT include the development and commercialization of its pipeline products, particularly in the rare disease space. The companys ability to secure regulatory approvals, manage clinical trials, and navigate the competitive landscape will significantly impact its financial performance. Additionally, SRPTs cash burn rate, research and development expenses, and potential partnerships or collaborations will influence its financial trajectory.
To make informed investment decisions, it is crucial to monitor SRPTs progress in its clinical trials, regulatory updates, and financial performance. A detailed analysis of the companys cash flows, operating expenses, and revenue growth will provide valuable insights into its potential for future profitability.
SRPT Stock Overview
| Market Cap in USD | 2,051m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1997-06-03 |
SRPT Stock Ratings
| Growth Rating | -72.1% |
| Fundamental | 38.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -88.7% |
| Analyst Rating | 4.38 of 5 |
SRPT Dividends
Currently no dividends paidSRPT Growth Ratios
| Growth Correlation 3m | -39.7% |
| Growth Correlation 12m | -94.2% |
| Growth Correlation 5y | 3% |
| CAGR 5y | -34.21% |
| CAGR/Max DD 5y | -0.37 |
| Sharpe Ratio 12m | -1.12 |
| Alpha | -106.83 |
| Beta | 1.231 |
| Volatility | 87.26% |
| Current Volume | 22536.2k |
| Average Volume 20d | 9413.4k |
| Stop Loss | 16.9 (-7.1%) |
| Signal | 0.15 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-58.0m TTM) > 0 and > 6% of Revenue (6% = 148.9m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA 7.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.00% (prev 132.6%; Δ -62.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -300.8m <= Net Income -58.0m (YES >=105%, WARN >=100%) |
| Net Debt (843.3m) to EBITDA (44.0m) ratio: 19.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (106.6m) change vs 12m ago 12.69% (target <= -2.0% for YES) |
| Gross Margin 78.85% (prev 87.71%; Δ -8.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.86% (prev 43.95%; Δ 25.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.26 (EBITDA TTM 44.0m / Interest Expense TTM 19.1m) >= 6 (WARN >= 3) |
Altman Z'' -2.88
| (A) 0.47 = (Total Current Assets 2.66b - Total Current Liabilities 919.9m) / Total Assets 3.68b |
| (B) -1.21 = Retained Earnings (Balance) -4.46b / Total Assets 3.68b |
| warn (B) unusual magnitude: -1.21 — check mapping/units |
| (C) -0.00 = EBIT TTM -5.01m / Avg Total Assets 3.55b |
| (D) -1.92 = Book Value of Equity -4.46b / Total Liabilities 2.32b |
| Total Rating: -2.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.67
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -10.35% = -5.0 |
| 3. FCF Margin -13.81% = -5.18 |
| 4. Debt/Equity 1.52 = 1.45 |
| 5. Debt/Ebitda 46.83 = -2.50 |
| 6. ROIC - WACC -5.58% = -6.98 |
| 7. RoE -4.42% = -0.74 |
| 8. Rev. Trend 95.22% = 4.76 |
| 9. Rev. CAGR 42.60% = 2.50 |
| 10. EPS Trend 53.95% = 1.35 |
| 11. EPS CAGR 42.10% = 2.50 |
What is the price of SRPT shares?
Over the past week, the price has changed by -9.99%, over one month by +14.97%, over three months by -52.86% and over the past year by -86.74%.
Is Sarepta Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SRPT is around 17.41 USD . This means that SRPT is currently overvalued and has a potential downside of -4.34%.
Is SRPT a buy, sell or hold?
- Strong Buy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SRPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.8 | 30.5% |
| Analysts Target Price | 90 | 394.3% |
| ValueRay Target Price | 18.9 | 3.7% |
Last update: 2025-08-20 02:49
SRPT Fundamental Data Overview
CCE Cash And Equivalents = 800.1m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 9.8425
P/S = 0.8265
P/B = 1.511
P/EG = 159.25
Beta = 0.455
Revenue TTM = 2.48b USD
EBIT TTM = -5.01m USD
EBITDA TTM = 44.0m USD
Long Term Debt = 1.14b USD (from longTermDebt, last quarter)
Short Term Debt = 919.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 2.06b USD (Calculated: Short Term 919.9m + Long Term 1.14b)
Net Debt = 843.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.31b USD (2.05b + Debt 2.06b - CCE 800.1m)
Interest Coverage Ratio = -0.26 (Ebit TTM -5.01m / Interest Expense TTM 19.1m)
FCF Yield = -10.35% (FCF TTM -342.7m / Enterprise Value 3.31b)
FCF Margin = -13.81% (FCF TTM -342.7m / Revenue TTM 2.48b)
Net Margin = -2.34% (Net Income TTM -58.0m / Revenue TTM 2.48b)
Gross Margin = 78.85% ((Revenue TTM 2.48b - Cost of Revenue TTM 525.0m) / Revenue TTM)
Tobins Q-Ratio = -0.74 (set to none) (Enterprise Value 3.31b / Book Value Of Equity -4.46b)
Interest Expense / Debt = 0.25% (Interest Expense 5.23m / Debt 2.06b)
Taxrate = 9.79% (from yearly Income Tax Expense: 25.5m / 260.8m)
NOPAT = -5.01m (EBIT -5.01m, no tax applied on loss)
Current Ratio = 2.89 (Total Current Assets 2.66b / Total Current Liabilities 919.9m)
Debt / Equity = 1.52 (Debt 2.06b / last Quarter total Stockholder Equity 1.36b)
Debt / EBITDA = 46.83 (Net Debt 843.3m / EBITDA 44.0m)
Debt / FCF = -6.01 (Debt 2.06b / FCF TTM -342.7m)
Total Stockholder Equity = 1.31b (last 4 quarters mean)
RoA = -1.57% (Net Income -58.0m, Total Assets 3.68b )
RoE = -4.42% (Net Income TTM -58.0m / Total Stockholder Equity 1.31b)
RoCE = -0.20% (Ebit -5.01m / (Equity 1.31b + L.T.Debt 1.14b))
RoIC = -0.20% (NOPAT -5.01m / Invested Capital 2.47b)
WACC = 5.38% (E(2.05b)/V(4.11b) * Re(10.55%)) + (D(2.06b)/V(4.11b) * Rd(0.25%) * (1-Tc(0.10)))
Shares Correlation 5-Years: 90.0 | Cagr: 7.49%
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -342.7m)
Revenue Correlation: 95.22 | Revenue CAGR: 42.60%
Rev Growth-of-Growth: 8.80
EPS Correlation: 53.95 | EPS CAGR: 42.10%
EPS Growth-of-Growth: -94.95
Additional Sources for SRPT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle